Fig. 2

Flow diagram of patient inclusion. BSV besifovir dipivoxil maleate, TAF tenofovir alafenamide fumarate, HCC hepatocellular carcinoma, HCV hepatitis C virus, HIV human immunodeficiency virus, TDF tenofovir disoproxil fumarate, ETV entecavir, PS propensity score.